Cabell Christopher 4
4 · ARENA PHARMACEUTICALS INC · Filed Jul 17, 2020
Insider Transaction Report
Form 4
Cabell Christopher
EVP, Head of R&D, and CMO
Transactions
- Exercise/Conversion
Common Stock
2020-07-15$26.28/sh+13,000$341,640→ 13,000 total - Exercise/Conversion
Employee Stock Option (right to buy)
2020-07-15−13,000→ 47,000 totalExercise: $26.28Exp: 2024-11-15→ Common Stock (13,000 underlying) - Sale
Common Stock
2020-07-15$68.00/sh−13,000$884,000→ 0 total
Footnotes (2)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
- [F2]The options vest over four years, with 25% of the shares subject to the option vesting on November 15, 2018, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.